drugset / Trial / NCT03723967
FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the phase II trial is to determine the efficacy and safety of a combination of Durvalumab with the Carboplatin/Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy.
Timeline
- Start
- 2019-05-16
- Primary completion
- 2020-05-16
- Completion
- 2024-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Paclitaxel | Small molecule | — | — |